Alefacept: profile report
- PDF / 78,611 Bytes
- 3 Pages / 667 x 914 pts Page_size
- 102 Downloads / 174 Views
9. 10.
11.
References 1. 2. 3. 4. 5.
6.
7.
8.
Evans H, Perry CM. Oregovomab. Am J Cancer 2003; 2 (2): 125-33 Berek JS. Oregovomab: a viewpoint. Am J Cancer 2003; 2 (2): 135 Baum RP. Oregovomab: a viewpoint. Am J Cancer 2003; 2 (2): 135-6 Brewer MA, Mitchell MF, Bast RC. Prevention of ovarian cancer. In Vivo 1999; 13 (1): 99-106 National Comprehensive Cancer Network. Ovarian cancer guideline [online]. Available from URL: http://www.nccn.org/ [Accessed 2003 Feb 25] Nicodemus CF, Schultes SC, Hamilton BL. Immunomodulation with antibodies: clinical application in ovarian cancer and other malignancies. Expert Rev. Vaccines 2002; 1 (1): 35-48 Bookman M, Rettenmaier M, Gordon A, et al. Monoclonal antibody (Oregovomab) targeting of CA125 in patients (Pts) with advanced epithelial ovarian cancer (EOC) and elevated CA125 after response to initial therapy [abstract no. 510]. Clin Cancer Res 2001; 7: 3756s AltaRex Corp. AltaRex announces positive OvaRex phase IIb results [media release]. 2002
12.
13.
14.
15.
AltaRex Corp. AltaRex presents OvaRex data at AACR conference [media release]. 2002 Berek J, Ehlen T, Gordon A, et al. Interim analysis of a double blind study of Ovarex mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer [abstract no. 837]. Proc Am Soc Clin Oncol 2001 May 12; 20: 210a Baum RP, Niesen A, Hertel A, et al. Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer 1994; 73: 1121-5 Schultes BC, Gordon A, Ehlen T, et al. Induction of tumorand CA125-specific T cell responses in patients (pts) with epithelial ovarian cancer (EOC) treated with OvaRex MAb-B43.13 [abstract no. 717]. Cancer Res 2002 Mar; 43: 144 Ehlen TG, Gordon AN, Fingert HJ, et al. Adjuvant treatment with monoclonal antibody, OvaRex MAb-B43.13 (OV) targeting CA125, induces robust immune responses associated with prolonged time to relapse (TTR) in a randomized, placebo-controlled study in patients (pts) with advanced epithelial ovarian cancer (EOC) [abstract no. 31]. Proc Am Soc Clin Oncol 2002 May 18; 21 (Pt 1): 9a Schultes BC, Nicodemus CF, Berek JS, et al. Use of OvaRex MAb-b43.13 as an immunotherapeutic treatment of epithelial ovarian cancer: experience as a single agent post first-line therapy and in combination with chemotherapy in recurrent disease [abstract; online]. Available from URL: http://www.eortc.be/ [Accessed 2002 Nov 26] Zhang L, Conejo-Garcia JR, Katsoros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-13
Alefacept: profile report Adapted and reproduced from Am J Clin Dermatol 2003; 4 (4): 277-287[1-3] Psoriasis is a chronic, relapsing, frequently inherited, inflammatory skin disease most commonly characterised by the appearance of well-demarcated erythematous plaques.[1] Chronic plaque psoriasis affects about 1–4% of the general population worldwide, and has a substantial socioeconomic impact. In the continuing absence of a cure for psoriasis, the goal of therapy is to improve symptoms so that
Data Loading...
